Caprock Group LLC Buys New Shares in Danaher Co. (NYSE:DHR)

Caprock Group LLC purchased a new position in shares of Danaher Co. (NYSE:DHR) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 15,214 shares of the conglomerate’s stock, valued at approximately $3,497,000.

Several other hedge funds have also recently made changes to their positions in DHR. Hamilton Point Investment Advisors LLC lifted its stake in Danaher by 0.7% in the fourth quarter. Hamilton Point Investment Advisors LLC now owns 41,799 shares of the conglomerate’s stock valued at $9,606,000 after buying an additional 296 shares during the period. Boomfish Wealth Group LLC increased its stake in shares of Danaher by 14.3% in the 4th quarter. Boomfish Wealth Group LLC now owns 3,743 shares of the conglomerate’s stock valued at $859,000 after acquiring an additional 468 shares in the last quarter. Norris Perne & French LLP MI lifted its position in shares of Danaher by 58.8% during the 4th quarter. Norris Perne & French LLP MI now owns 130,356 shares of the conglomerate’s stock valued at $29,923,000 after acquiring an additional 48,261 shares during the period. Strategic Wealth Investment Group LLC boosted its stake in Danaher by 11.5% during the fourth quarter. Strategic Wealth Investment Group LLC now owns 41,176 shares of the conglomerate’s stock worth $9,452,000 after acquiring an additional 4,263 shares in the last quarter. Finally, Gilbert & Cook Inc. grew its holdings in Danaher by 2.5% in the fourth quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock worth $401,000 after purchasing an additional 42 shares during the period. 79.05% of the stock is owned by institutional investors.

Danaher Stock Performance

NYSE:DHR opened at $222.56 on Friday. The company has a market capitalization of $160.75 billion, a P/E ratio of 42.15, a P/E/G ratio of 4.22 and a beta of 0.83. The business has a fifty day simple moving average of $235.66 and a two-hundred day simple moving average of $253.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 1 year low of $221.34 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.72% and a net margin of 16.33%. During the same period last year, the company posted $2.09 earnings per share. On average, analysts expect that Danaher Co. will post 8.15 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.49%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s payout ratio is currently 20.45%.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 11.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research report on Thursday, October 31st. Wells Fargo & Company cut their price target on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a report on Friday, December 13th. Citigroup cut their target price on Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a report on Thursday. Finally, UBS Group decreased their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.